Rachael Dickman

Dr. Rachael Dickman

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2017 in Journal of the American Chemical Society
Verified
Journal Article
Open access
ZWZoë V. F. Wright
Zoë V. F. Wright
SMStephen McCarthy
Stephen McCarthy
Rachael DickmanRachael Dickman
Rachael Dickman
FRFrancis E. Reyes
Francis E. Reyes
SSSilvia Sanchez-Martinez
Silvia Sanchez-Martinez
ATAlethea B. Tabor
Alethea B. Tabor
Spider venom toxins, such as Protoxin-II (ProTx-II), have recently received much attention as selective Nav1.7 channel blockers, with potential to be developed as leads for the treatment of chronic nocioceptive pain. ProTx-II is a 30-amino acid peptide with three disulfide bonds that has been reported to adopt a well-defined inhibitory cystine knot (ICK) scaffold structure. Potential drawbacks with such peptides include poor pharmacodynamics and potential scrambling of the disulfide bonds in vivo. In order to address these issues, in the present study we report the solid-phase synthesis of lanthionine-bridged analogues of ProTx-II, in which one of the three disulfide bridges is replaced with a thioether linkage, and evaluate the biological properties of these analogues. We have also investigated the folding and disulfide bridging patterns arising from different methods of oxidation of the linear peptide precursor. Finally, we report the X-ray crystal structure of ProTx-II to atomic resolution; to our knowledge this is the first crystal structure of an ICK spider venom peptide not bound to a substrate.

29 August 2019 in The Journal of Organic Chemistry
Verified
Journal Article
Open access
Rachael DickmanRachael Dickman
Rachael Dickman
SMSerena A. Mitchell
Serena A. Mitchell
AFAngelo M. Figueiredo
Angelo M. Figueiredo
DHD. Flemming Hansen
D. Flemming Hansen
ATAlethea B. Tabor
Alethea B. Tabor
In response to the growing threat posed by antibiotic-resistant bacterial strains, extensive research is currently focused on developing antimicrobial agents that target lipid II, a vital precursor in the biosynthesis of bacterial cell walls. The lantibiotic nisin and related peptides display unique and highly selective binding to lipid II. A key feature of the nisin–lipid II interaction is the formation of a cage-like complex between the pyrophosphate moiety of lipid II and the two thioether-bridged rings, rings A and B, at the N-terminus of nisin. To understand the important structural factors underlying this highly selective molecular recognition, we have used solid-phase peptide synthesis to prepare individual ring A and B structures from nisin, the related lantibiotic mutacin, and synthetic analogues. Through NMR studies of these rings, we have demonstrated that ring A is preorganized to adopt the correct conformation for binding lipid II in solution and that individual amino acid substitutions in ring A have little effect on the conformation. We have also analyzed the turn structures adopted by these thioether-bridged peptides and show that they do not adopt the tight α-turn or β-turn structures typically found in proteins.

10 June 2023 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Open access
EAEmily Anne Atkinson
Emily Anne Atkinson
Rachael DickmanRachael Dickman
Rachael Dickman
Traumatic brain injury (TBI) is a leading cause of disability in adults, caused by a physical insult damaging the brain. Growth factor-based therapies have the potential to reduce the effects of secondary injury and improve outcomes by providing neuroprotection against glutamate excitotoxicity, oxidative damage, hypoxia, and ischemia, as well as promoting neurite outgrowth and the formation of new blood vessels. Despite promising evidence in preclinical studies, few neurotrophic factors have been tested in clinical trials for TBI. Translation to the clinic is not trivial and is limited by the short in vivo half-life of the protein, the inability to cross the blood-brain barrier and human delivery systems. Synthetic peptide mimetics have the potential to be used in place of recombinant growth factors, activating the same downstream signalling pathways, with a decrease in size and more favourable pharmacokinetic properties. In this review, we will discuss growth factors with the potential to modulate damage caused by secondary injury mechanisms following a traumatic brain injury that have been trialled in other indications including spinal cord injury, stroke and neurodegenerative diseases. Peptide mimetics of nerve growth factor (NGF), hepatocyte growth factor (HGF), glial cell line-derived growth factor (GDNF), brain-derived neurotrophic factor (BDNF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) will be highlighted, most of which have not yet been tested in preclinical or clinical models of TBI.

1 November 2018 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Open access
SMSerena A. Mitchell
Serena A. Mitchell
FTFiona Truscott
Fiona Truscott
Rachael DickmanRachael Dickman
Rachael Dickman
JWJohn M. Ward
John M. Ward
ATAlethea B. Tabor
Alethea B. Tabor
New designs of antimicrobial peptides are urgently needed in order to combat the threat posed by the recent increase of resistance to antibiotics. In this paper, we present a new series of antimicrobial peptides, based on the key structural features of the lantibiotic nisin. We have simplified the structure of nisin by conjugating the lipid II-binding motif at the N-terminus of nisin to a series of cationic peptides and peptoids with known antibacterial action and pore-forming properties. Hybrid peptides, where a hydrophilic PEG4 linker was used, showed good antibacterial activity against Micrococcus luteus.

10 October 2019 in Chemistry – A European Journal
Verified
Journal Article
Open access
PDF file
Rachael DickmanRachael Dickman
Rachael Dickman
EDEmma Danelius
Emma Danelius
SMSerena A. Mitchell
Serena A. Mitchell
DHD. Flemming Hansen
D. Flemming Hansen
MEMate Erdelyi
Mate Erdelyi
ATAlethea B. Tabor
Alethea B. Tabor
Natural products that target lipid II, such as the lantibiotic nisin, are strategically important in the development of new antibacterial agents to combat the rise of antimicrobial resistance. Understanding the structural factors that govern the highly selective molecular recognition of lipid II by the N‐terminal region of nisin, nisin(1–12), is a crucial step in exploiting the potential of such compounds. In order to elucidate the relationships between amino acid sequence and conformation of this bicyclic peptide fragment, we have used solid‐phase peptide synthesis to prepare two novel analogues of nisin(1–12) in which the dehydro residues have been replaced. We have carried out an NMR ensemble analysis of one of these analogues and of the wild‐type nisin(1–12) peptide in order to compare the conformations of these two bicyclic peptides. Our analysis has shown the effects of residue mutation on ring conformation. We have also demonstrated that the individual rings of nisin(1–12) are pre‐organised to an extent for binding to the pyrophosphate group of lipid II, with a high degree of flexibility exhibited in the central amide bond joining the two rings.

4 January 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MSMousumi Shyam
Mousumi Shyam
HVHarshita Verma
Harshita Verma
GBGourab Bhattacharje
Gourab Bhattacharje
PMPiyali Mukherjee
Piyali Mukherjee
SSSamsher Singh
Samsher Singh
VJVenkatesan Jayaprakash
Venkatesan Jayaprakash